OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Patel on ADCs in Early-Stage NSCLC

January 7th 2025

Sandip P. Patel, MD, discusses the potential role of antibody-drug conjugates in early-stage non–small cell lung cancer.

Dr Phull on the Efficacy and Safety of Cilta-Cel vs Ide-Cel in R/R Multiple Myeloma

January 7th 2025

Pooja Phull, MD, discusses the use of ciltacabtagene autoleucel and idecabtagene vicleucel in R/R multiple myeloma.

Dr Bhatnagar on AlloSCT Outcomes After Blinatumomab/Chemo in MRD-Negative B-ALL

January 7th 2025

Bhavana Bhatnagar, DO, discusses outcomes for allogeneic stem cell transplantation after blinatumomab plus chemotherapy in B-ALL.

Dr Emadi on Initial Responses With Venetoclax Plus PegC in R/R AML

January 6th 2025

Ashkan Emadi, MD, PhD, discusses responses achieved with venetoclax plus PegC in patients with venetoclax-pretreated, relapsed/refractory AML.

Dr LeVee on Immune-Related AEs Associated With ICIs in Early Breast Cancer

January 6th 2025

Alexis LeVee, MD, discusses immune-related adverse effects in patients with early breast cancer treated with immune checkpoint inhibitors.

Dr Dreyling on the Role of ASCT in Ibrutinib-Containing First-Line Therapy for Younger Patients With MCL

January 6th 2025

Martin Dreyling, MD, discusses the role of autologous stem cell transplantation (ASCT) in the context of ibrutinib-containing first-line therapy for younger patients with MCL.

Dr van Meerten on the Efficacy and Safety of Brexu-Cel in BTK Inhibitor–Naive R/R MCL

January 6th 2025

Tom van Meerten, MD, PhD, discusses the efficacy and safety of brexucabtagene autoleucel in BTK inhibitor–naive relapsed/refractory MCL.

Dr Strickler on the Development of Telisotuzumab Adizutecan in MET-Amplified Gastric Cancer

January 6th 2025

John H. Strickler, MD, discusses the rationale for developing telisotuzumab adizutecan in MET gene–amplified advanced gastric cancer.

Dr Li on Neoadjuvant SHR-A1811 in HER2+ Breast Cancer

January 3rd 2025

Junjie Li, MD, discusses the efficacy of neoadjuvant SHR-A1811, a HER2-directed antibody-drug conjugate, in HER2-positive breast cancer.

Dr Riedell on Efficacy and Safety of Rapcabtagene Autoleucel in R/R DLBCL

January 3rd 2025

Peter Riedell, MD, discusses efficacy and safety of rapcabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr Cortes on Asciminib’s Superior Efficacy and Safety in First-Line CML

January 2nd 2025

Jorge Cortes, MD, discusses asciminib’s sustained efficacy and improved safety over other TKIs in first-line CML.

Dr Bishop on 34-Month Data With Anitocabtagene Autoleucel in R/R Myeloma

December 23rd 2024

Michael R. Bishop, MD, discusses 34-month data from the iMMagine-1 trial of anitocabtagene autoleucel in relapsed/refractory myeloma.

Dr Leslie on the 5-Year Follow-Up of the ZUMA-5 Trial in R/R Indolent NHL

December 23rd 2024

Meta: Lori A Leslie, MD, discusses 5-year follow-up data from the ZUMA-5 trial evaluating axi-cel in relapsed/refractory indolent non-Hodgkin lymphoma.

Dr Ip on Comparative Findings Between CAR T-Cell Therapies in LBCL

December 20th 2024

Andrew Ip, MD, discusses comparative real-world outcomes of commercial CD19-directed CAR T-cell therapies in large B-cell lymphoma.

Dr Shah on the Effects of IVIG on Teclistamab-Associated Infection Risk in Myeloma

December 20th 2024

Mansi R. Shah, MD, on the effects of IVIG on infections in recipients of teclistamab therapy for multiple myeloma.

Dr Buchbinder on the Potential Role for RP1 Plus Nivolumab in Melanoma After PD-1 Progression

December 20th 2024

Elizabeth Buchbinder, MD, discusses the implications of the FDA's decision to grant breakthrough therapy designation to RP1 plus nivolumab in melanoma.

Dr Garmezy on the Rationale for Developing Zelenectide Pevedotin in Urothelial Cancer

December 20th 2024

Benjamin Garmezy, MD, discusses the rationale for developing zelenectide pevedotin in metastatic urothelial carcinoma.

Dr Watson on the Use of Oncogene Analysis to Determine Clinically Relevant HER2, KRAS and MET Copy-Number Gain in NSCLC

December 20th 2024

Alec Watson, MD, discusses clinically relevant thresholds for HER2, KRAS, and MET gene copy number gain set by oncogene overlap analysis in NSCLC.

Dr Sardesai on Lasofoxifene Plus Abemaciclib in ESR1-Mutant, ER+/HER2– Breast Cancer

December 19th 2024

Sagar D. Sardesai, MBBS, discusses the phase 3 ELAINE-3 trial evaluating lasofoxifene plus abemaciclib in ESR1-mutant, ER-positive, HER2-negative breast cancer.

Dr Baker on the EMBRACE Trial of the Dxcover Liquid Biopsy in Brain Cancer

December 19th 2024

Matthew J. Baker, PhD, discusses the ongoing investigation of the Dxcover Liquid Biopsy for patients with brain cancer in the EMBRACE study.